Donald E. Bobo, Jr. Sells 5,300 Shares of Edwards Lifesciences Corporation (EW) Stock

Edwards Lifesciences Corporation (NYSE:EW) VP Donald E. Bobo, Jr. sold 5,300 shares of the firm’s stock in a transaction on Friday, July 28th. The stock was sold at an average price of $114.68, for a total transaction of $607,804.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Donald E. Bobo, Jr. also recently made the following trade(s):

  • On Friday, August 4th, Donald E. Bobo, Jr. sold 25,000 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $116.00, for a total transaction of $2,900,000.00.
  • On Thursday, June 29th, Donald E. Bobo, Jr. sold 5,600 shares of Edwards Lifesciences Corporation stock. The stock was sold at an average price of $117.15, for a total transaction of $656,040.00.
  • On Monday, May 8th, Donald E. Bobo, Jr. sold 19,100 shares of Edwards Lifesciences Corporation stock. The shares were sold at an average price of $110.34, for a total transaction of $2,107,494.00.
  • On Thursday, May 4th, Donald E. Bobo, Jr. sold 34,120 shares of Edwards Lifesciences Corporation stock. The shares were sold at an average price of $109.98, for a total transaction of $3,752,517.60.

Shares of Edwards Lifesciences Corporation (NYSE EW) traded down 0.41% during mid-day trading on Friday, reaching $113.11. 1,134,626 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $116.42 and its 200-day moving average price is $106.02. The company has a market capitalization of $23.88 billion, a PE ratio of 34.31 and a beta of 0.63. Edwards Lifesciences Corporation has a one year low of $81.12 and a one year high of $121.75.

Edwards Lifesciences Corporation (NYSE:EW) last issued its quarterly earnings results on Wednesday, July 26th. The medical research company reported $1.08 EPS for the quarter, topping the consensus estimate of $0.88 by $0.20. The company had revenue of $842 million during the quarter, compared to analyst estimates of $839.16 million. Edwards Lifesciences Corporation had a net margin of 22.16% and a return on equity of 27.17%. The firm’s revenue was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.76 EPS. On average, equities analysts expect that Edwards Lifesciences Corporation will post $3.78 earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: This story was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.com-unik.info/2017/08/19/donald-e-bobo-jr-sells-5300-shares-of-edwards-lifesciences-corporation-ew-stock-updated-updated.html.

Large investors have recently modified their holdings of the company. ETF Managers Group LLC bought a new stake in shares of Edwards Lifesciences Corporation during the second quarter valued at approximately $112,000. YorkBridge Wealth Partners LLC bought a new stake in shares of Edwards Lifesciences Corporation during the first quarter valued at approximately $110,000. NEXT Financial Group Inc raised its stake in shares of Edwards Lifesciences Corporation by 91.7% in the first quarter. NEXT Financial Group Inc now owns 1,045 shares of the medical research company’s stock valued at $115,000 after buying an additional 500 shares during the last quarter. Shine Investment Advisory Services Inc. bought a new stake in shares of Edwards Lifesciences Corporation during the second quarter valued at approximately $126,000. Finally, Cornerstone Advisors Inc. boosted its stake in shares of Edwards Lifesciences Corporation by 25.1% in the second quarter. Cornerstone Advisors Inc. now owns 1,092 shares of the medical research company’s stock valued at $129,000 after buying an additional 219 shares during the period. 84.67% of the stock is owned by institutional investors.

A number of equities research analysts have recently weighed in on EW shares. Vetr lowered shares of Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating and set a $124.67 target price on the stock. in a research note on Monday, May 15th. Zacks Investment Research raised shares of Edwards Lifesciences Corporation from a “hold” rating to a “buy” rating and set a $125.00 target price on the stock in a research note on Monday, May 22nd. Goldman Sachs Group, Inc. (The) started coverage on shares of Edwards Lifesciences Corporation in a research note on Tuesday, May 16th. They set a “conviction-buy” rating and a $138.00 target price on the stock. Canaccord Genuity reaffirmed a “buy” rating and set a $150.00 target price on shares of Edwards Lifesciences Corporation in a research note on Wednesday, June 28th. Finally, Barclays PLC boosted their price objective on shares of Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 27th. Five investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $121.13.

Edwards Lifesciences Corporation Company Profile

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

What are top analysts saying about Edwards Lifesciences Corporation? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Edwards Lifesciences Corporation and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit